Yiran Si

Key Laboratory Of Breast Cancer Prevention And Therapy, Key Laboratory Of Cancer Immunology And Biotherapy
Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity.

The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity.

Journal: Cancers

Published: November 19, 2025

AGEs induce MMP-9 promoter demethylation through the GADD45α-mediated BER pathway to promote breast cancer metastasis in patients with diabetes.

AGEs induce MMP-9 promoter demethylation through the GADD45α-mediated BER pathway to promote breast cancer metastasis in patients with diabetes.

Journal: Endocrine-related cancer

Published: November 27, 2023

Bioinformatics analysis of human kallikrein 5 (KLK5) expression in metaplastic triple-negative breast cancer.

Bioinformatics analysis of human kallikrein 5 (KLK5) expression in metaplastic triple-negative breast cancer.

Journal: Cancer innovation

Published: May 22, 2023

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.

Journal: Cancer biology & medicine

Published: March 02, 2023

Retraction Notice to: Exosome miR-155 Derived from Gastric Carcinoma Promotes Angiogenesis by Targeting the c-MYB/VEGF Axis of Endothelial Cells.

Retraction Notice to: Exosome miR-155 Derived from Gastric Carcinoma Promotes Angiogenesis by Targeting the c-MYB/VEGF Axis of Endothelial Cells.

Journal: Molecular therapy. Nucleic acids

Published: March 23, 2022

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy.

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy.

Journal: Current cancer drug targets

Published: September 30, 2021

Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients.

Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients.

Journal: Journal of Cancer

Published: August 28, 2021

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer.

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer.

Journal: Cancer biology & medicine

Published: March 12, 2021

Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer.

Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer.

Journal: Biomarker research

Published: January 11, 2021

The emerging role of RNA N6-methyladenosine methylation in breast cancer.

The emerging role of RNA N6-methyladenosine methylation in breast cancer.

Journal: Biomarker research

Published: January 10, 2021

Phase-Transformation Nanoparticle-Mediated Sonodynamic Therapy: An Effective Modality to Enhance Anti-Tumor Immune Response by Inducing Immunogenic Cell Death in Breast Cancer.

Phase-Transformation Nanoparticle-Mediated Sonodynamic Therapy: An Effective Modality to Enhance Anti-Tumor Immune Response by Inducing Immunogenic Cell Death in Breast Cancer.

Journal: International journal of nanomedicine

Published: December 17, 2020

A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer.

A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer.

Journal: Frontiers in oncology

Published: October 19, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026